Biogen Inc (BIIB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-18. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.05% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- A kidney transplant milestone has Wall Street excited about Biogen
- Biogen-backed Estuary nabs $93M for kidney disease gene therapy
- Biogen’s Quarterly Earnings Preview: What You Need to Know
- Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
- Biogen (BIIB) Stock Is Up, What You Need To Know
- Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom
- What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders
- Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Biogen Inc.
Full BIIB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.